Table 3.
Multivariate analysis of variables correlated with the treatment regimen status and other prognostic factors
| HR | Cl (95%) | P value | |
|---|---|---|---|
| Disease-free survival | |||
| Treatment regimen status | |||
| CCRT | Reference | ||
| CTX/NTZ plus CCRT | 0.57 | 0.35-0.92 | 0.021 |
| Gender | |||
| Female | Reference | ||
| Male | 1.22 | 0.89-1.67 | 0.221 |
| Age | |||
| <45 | Reference | ||
| ≥45 | 1.15 | 0.88-1.49 | 0.307 |
| Karnofsky performance status score | |||
| 70-80 | Reference | ||
| 90-100 | 1.17 | 0.63-1.65 | 0.497 |
| Tumor stage | |||
| T1-T3 | Reference | ||
| T4 | 2.80 | 1.10-7.10 | 0.030 |
| Node stage | |||
| N0-N1 | Reference | ||
| N2 | 1.46 | 1.11-1.93 | 0.007 |
| N3 | 3.96 | 1.66-9.45 | 0.002 |
| Disease stage | |||
| II-III | Reference | ||
| IV | 0.65 | 0.25-1.72 | 0.386 |
| Loco-regional relapse-free survival | |||
| Treatment regimen status | |||
| CCRT | Reference | ||
| CTX/NTZ plus CCRT | 0.54 | 0.25-1.18 | 0.122 |
| Gender | |||
| Female | Reference | ||
| Male | 1.14 | 0.71-1.84 | 0.591 |
| Age | |||
| <45 | Reference | ||
| ≥45 | 1.04 | 0.70-1.56 | 0.846 |
| Karnofsky performance status score | |||
| 70-80 | Reference | ||
| 90-100 | 0.98 | 0.57-3.56 | 0.658 |
| Tumor stage | |||
| T1-T3 | Reference | ||
| T4 | 4.65 | 0.94-23.00 | 0.060 |
| Node stage | |||
| N0-N1 | Reference | ||
| N2 | 1.23 | 0.80-1.90 | 0.350 |
| N3 | 4.76 | 1.14-19.90 | 0.032 |
| Disease stage | |||
| II-III | Reference | ||
| IV | 0.31 | 0.06-1.66 | 0.173 |
| Distant metastasis-free survival | |||
| Treatment regimen status | |||
| CCRT | Reference | ||
| CTX/NTZ plus CCRT | 0.55 | 0.31-0.91 | 0.031 |
| Gender | |||
| Female | Reference | ||
| Male | 1.50 | 1.02-2.22 | 0.042 |
| Age | |||
| <45 | Reference | ||
| ≥45 | 1.08 | 0.79-1.46 | 0.639 |
| Karnofsky performance status score | |||
| 70-80 | Reference | ||
| 90-100 | 1.01 | 0.74-1.52 | 0.892 |
| Tumor stage | |||
| T1-T3 | Reference | ||
| T4 | 1.58 | 0.55-4.54 | 0.400 |
| Node stage | |||
| N0-N1 | Reference | ||
| N2 | 1.52 | 1.10-2.11 | 0.011 |
| N3 | 2.89 | 1.04-8.07 | 0.043 |
| Disease stage | |||
| II-III | Reference | ||
| IV | 1.31 | 0.43-3.93 | 0.635 |
| Overall survival | |||
| Treatment regimen status | |||
| CCRT | Reference | ||
| CTX/NTZ plus CCRT | 0.40 | 0.19-0.82 | 0.012 |
| Gender | |||
| Female | Reference | ||
| Male | 1.30 | 0.86-1.97 | 0.219 |
| Age | |||
| <45 | Reference | ||
| ≥45 | 1.44 | 1.02-2.02 | 0.039 |
| Karnofsky performance status score | |||
| 70-80 | Reference | ||
| 90-100 | 0.88 | 0.34-1.96 | 0.412 |
| Tumor stage | |||
| T1-T3 | Reference | ||
| T4 | 3.32 | 1.12-9.89 | 0.031 |
| Node stage | |||
| N0-N1 | Reference | ||
| N2 | 1.75 | 1.23-2.50 | 0.002 |
| N3 | 5.23 | 1.90-14.40 | 0.001 |
| Disease stage | |||
| II-III | Reference | ||
| IV | 0.64 | 0.20-2.02 | 0.443 |
The data originate from 1628 patients included in the study. HR, hazard ratio; 95% CI, 95% confidence interval.